GSK acquires T cell-engager for multiple myeloma treatment
London - Pharmaceutical giant GSK has acquired a trispecific T cell-engager from privately held biotech firm Chimagen Biosciences, aimed at treating multiple myeloma, according to a press release. The innovative drug can bind to T cells while simultaneously targeting two tumor-associated antigens. Once in phase I trials in 2027, GSK will pay an upfront fee to secure global rights to the treatment.
Chimagen will receive development and commercial milestone payments. The $750 million agreement, subject to customary conditions, bolsters GSK's oncology portfolio and advances its blood cancer leadership goals, said Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D at GSK.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
